Haemoptysis

Meet the patient

A 58-year-old smoker walks into the ED at 4am holding a bowl of bright red frothy blood — half a cup, by his wife's estimate, in the last hour. His CXR shows a spiculated right upper lobe mass, his fingers are clubbed, and he has lost ten kilos without trying.^[1][3]

Two exam questions are now live, and they are the two that decide every haemoptysis: where is the blood coming from? and is he about to drown in it? The first question sorts the differential — TB, cancer, bronchiectasis, PE, a pulmonary-renal syndrome; the second sorts the disposition — outpatient bronchoscopy or rigid scope and BAE tonight.^[1][4]

Hold those two questions and everything below slots into place. The single non-negotiable fact to carry through this topic: massive haemoptysis kills by asphyxia, not by exsanguination — so the airway comes first, always, before the CT and before the diagnosis.^[1][5]

What haemoptysis is — and the three things it isn't

Haemoptysis is the expectoration of blood that originates from the respiratory tract below the vocal cords — i.e. from the trachea, bronchi, bronchioles or lung parenchyma.^[3] The word itself (haima, blood + ptysis, to spit) names the act: blood that is coughed from the airway, not vomited from the stomach or swallowed from the nose. Defining the source as below the vocal cords is what separates true haemoptysis from its mimics, and it is the single most important bedside distinction to make before any investigation is ordered.

It must be distinguished at the bedside from two mimics: ^[1]

• Haematemesis — vomiting blood from the upper GI tract. Haemoptysis is bright red, frothy, alkaline and coughed up; it is mixed with sputum and may continue over several days. Haematemesis is dark ('coffee-ground'), acidic and vomited, often with a history of liver disease, peptic ulcer or dyspepsia. (In practice, aspiration of haematemesis and swallowing of haemoptysis blur the picture — a careful history of the act — cough vs vomit — is decisive.)
• Pseudohaemoptysis — blood from the upper airway (epistaxis, gingival disease, pharyngeal or laryngeal lesion) or factitious (food dye, Munchausen). Always inspect the nose, oropharynx and upper airway before concluding the blood is pulmonary.^[3]

^[1]

The clinical skill in haemoptysis is triage: deciding who is stable for an outpatient work-up (mild, self-limiting, no red flags) versus who needs emergency airway protection, bronchoscopy and BAE (massive/life-threatening). Volume alone is a poor discriminator — a small bleed in a patient with a poor cough or limited respiratory reserve can kill.^[1][4]

Classification

Haemoptysis is classified by volume/severity (which drives the urgency and site of care) and by source (bronchial arterial vs pulmonary capillary). Volume thresholds have historically varied widely, which is why the modern trend is toward a functional definition.^[3]

^{[1] [4] [8]}

Enlarge

^{[1] [4] [8] [14] [2]}

Epidemiology & Risk Factors

Haemoptysis accounts for a substantial minority of respiratory presentations — roughly one in a thousand emergency attendances, and it is the presenting feature in a significant fraction of lung cancer and TB diagnoses. The aetiology is geography-dependent:^[3]

• Worldwide / TB-endemic regions (India, South Asia, sub-Saharan Africa): tuberculosis is the commonest cause — both active disease (cavitary, endobronchial) and the late sequelae Rasmussen aneurysm, post-TB bronchiectasis and aspergilloma colonising an old TB cavity.
• Developed countries: bronchial carcinoma, bronchiectasis, pneumonia/lung abscess, pulmonary embolism; chronic bronchitis in smokers.
• The cause remains unknown in about half of all cases; among recognised causes, infectious and inflammatory airway disease (about 26 percent) and cancer (about 17 percent) lead — so follow-up imaging matters, because an occult malignancy can declare itself over months.^[3]

Cryptogenic haemoptysis deserves emphasis: when CXR, CT and bronchoscopy are all normal, a small proportion of these "idiopathic" cases turn out to harbour a bronchial carcinoma that declares itself on follow-up — which is why repeat imaging is mandatory in smokers and older patients, and why "cryptogenic" is a diagnosis of exclusion made only after a complete work-up, never a reassurance.^[3]

Causes of MASSIVE (life-threatening) haemoptysis differ in rank from mild haemoptysis: the leading sources are bronchiectasis (including cystic fibrosis), lung carcinoma, active TB / mycetoma (aspergilloma), chronic necrotising aspergillosis, and pulmonary arteriovenous malformations (Osler–Weber–Rendu). Mild haemoptysis, by contrast, is most often bronchitis (smoker's) or a post-infective cough. This distinction — that bronchitis heads the list for mild bleeds while bronchiectasis heads the list for massive bleeds — is a favourite examiner question.^[1][2]

^{[3] [4] [7] [8] [14]}

Risk factors (high-yield associations): ^[1]

• Smoking, age over 40 — bronchial carcinoma (the single most important red-flag combination).
• Chronic lung disease — bronchiectasis (incl. cystic fibrosis), COPD, previous TB cavity (aspergilloma).
• Immunosuppression — invasive aspergillosis, TB reactivation, CMV, thrombocytopenia.
• Anticoagulation / antiplatelet therapy / coagulopathy — these unmask an occult lesion rather than cause bleed de novo; never assume the drug is the sole cause.
• Recent procedure — bronchoscopy with biopsy, transthoracic needle biopsy, pulmonary artery catheter (Swan–Ganz) — risk of iatrogenic PA rupture.
• Structural heart disease — mitral stenosis (rare but classic), left-heart failure.
• Vascular / hereditary — hereditary haemorrhagic telangiectasia (Osler–Weber–Rendu) with pulmonary AVM.
• Connective tissue / vasculitis — ANCA-associated vasculitis, anti-GBM disease, SLE, IgA nephropathy, antiphospholipid syndrome.
• Recreational drugs — cocaine (parenchymal damage), and occupational (trimellitic anhydride). ^[1]

Pathophysiology

The lung has a dual blood supply, and understanding it is the key to haemoptysis:^[1][4]

• Pulmonary circulation — the low-pressure (mean about 15 mmHg) system carrying the entire cardiac output through the pulmonary capillary bed for gas exchange. Bleeding here tends to be diffuse (diffuse alveolar haemorrhage) and low-pressure, so it oozes rather than spurts.
• Bronchial circulation — the high-pressure systemic supply (aorta, mean about 100 mmHg) that nourishes the airways and is responsible for over 90 percent of massive haemoptysis. When a bronchial artery erodes into a bronchus (carcinoma, bronchiectasis, mycetoma, TB cavity), the high pressure produces brisk, voluminous bleeding that floods the airway. ^[1]

This dual anatomy is also why bronchial artery embolisation works: the culprit vessel is a systemic artery reachable from the aorta by an interventional radiologist, not the fragile pulmonary capillary bed. ^[1]

Mechanisms by cause:^[3][4]

• Bronchiectasis / chronic infection — chronic airway inflammation causes hypertrophy and neo-vascularisation of the bronchial arteries (angiogenesis driven by chronic inflammation); the enlarged, tortuous, high-pressure vessels lie submucosally and rupture into the lumen. This is the commonest cause of massive haemoptysis in many series.
• Bronchogenic carcinoma — direct tumour invasion of bronchial vessels, tumour neo-angiogenesis, and necrosis of a vascular tumour bed.
• Tuberculosis — endobronchial disease, cavitary erosion, and the Rasmussen aneurysm (a pseudoaneurysm of a pulmonary artery branch in the wall of a chronic TB cavity that ruptures into the cavity and airway).
• Aspergilloma (mycetoma) — the fungus ball and its surrounding granulation tissue erode the highly vascular cavity wall; massive, recurrent haemoptysis is characteristic.
• Pulmonary embolism — infarction of a segment with haemorrhagic necrosis produces blood-tinged sputum (usually modest volume).
• Diffuse alveolar haemorrhage — capillaritis (ANCA, anti-GBM) or bland bleeding (coagulopathy, mitral stenosis) floods alveoli; haemoptysis may be absent because the blood stays in the alveolar space and is reabsorbed, leaving the patient anaemic with bilateral infiltrates but no coughed blood. ^[1]

Diffuse alveolar haemorrhage in more detail: DAH arises from injury to the pulmonary capillary bed. In capillaritis (the commoner, more dangerous form) neutrophils attack the capillary wall in ANCA-associated vasculitis (GPA, MPA, EGPA), anti-GBM disease (Goodpasture) and immune-complex disease (SLE, IgA nephropathy, antiphospholipid syndrome) — blood leaks into the alveolar space and the patient develops a pulmonary–renal syndrome (alveolar bleeding plus rapidly progressive glomerulonephritis). In bland DAH there is no inflammation — the capillaries simply ooze because of coagulopathy, mitral stenosis (raised pulmonary venous pressure), drugs (propylthiouracil, penicillamine) or toxins (trimellitic anhydride, cocaine). Bronchoalveolar lavage is diagnostic: progressively bloodier returns from sequential aliquots confirm ongoing alveolar bleeding.^[4]

Why the source matters for treatment: because over 90 percent of massive bleeds come from the high-pressure bronchial arteries, the definitive therapy targets that circulation — bronchial artery embolisation from the aorta. The pulmonary capillary bleeds (DAH) are instead treated by immunosuppression (steroids, cyclophosphamide, plasma exchange), not embolisation. Identifying the source on CT angiography therefore changes the entire management pathway.^[1]

Why massive haemoptysis kills: unlike other haemorrhage, even a small amount of blood can rapidly flood the airways, impairing oxygenation and ventilation and causing asphyxia and consequent cardiovascular collapse long before exsanguination. Airway protection, not volume resuscitation, is therefore the first priority.^[1][5]

Enlarge

^{[1] [7]}

Causes by Category

The examiner expects the causes organised by anatomical source, because the source determines the investigation pathway and the intervention. Work through the categories in this order, and decide the most likely from the clinical picture.^[2][3][4]

Three-way differentiation the examiner always wants:^[3]

1. Bronchial carcinoma — smoker over 40, weight loss, clubbing, central or peripheral mass on imaging, persistent haemoptysis; cytology/biopsy diagnostic.
2. Pulmonary TB — younger, fever/night sweats, apical cavity, sputum AFB-positive, high local prevalence.
3. Bronchiectasis — years of chronic purulent sputum, clubbing, tram-track/signet-ring on HRCT.
4. Pulmonary embolism — sudden dyspnoea and pleuritic pain, clear CXR (or wedge infarct), risk factors; CTPA filling defect.
5. Mitral stenosis — rare but classic — mid-diastolic murmur, AF, orthopnoea, normal CXR or pulmonary oedema. ^[1]

Clinical Presentation

History — establish the act (cough vs vomit), the volume, the colour (bright red/fresh vs dark), whether it is mixed with sputum or pure blood, the duration and frequency (one episode vs recurrent), and associated symptoms. Bright red, frothy, alkaline blood mixed with sputum that is coughed = true haemoptysis.^[3]

Associated features that localise the cause: ^[1]

• Fever, night sweats, weight loss, chronic cough, apical infiltrate — TB.
• Smoker over 40, weight loss, clubbing, haemoptysis out of proportion to symptoms, new mass — bronchial carcinoma.
• Years of chronic daily purulent sputum, recurrent infections, clubbing — bronchiectasis.
• Sudden dyspnoea, pleuritic chest pain, clear CXR, risk factors (immobility, malignancy, pregnancy, recent surgery) — PE.
• Dyspnoea, bilateral infiltrates, acute kidney injury, haematuria — diffuse alveolar haemorrhage (ANCA, anti-GBM).
• Orthopnoea, mitral facies, mid-diastolic murmur, AF — mitral stenosis.
• Epistaxis, telangiectasia, family history — Osler–Weber–Rendu (pulmonary AVM).
• Recent bronchoscopy/biopsy, PA catheter in situ, anticoagulants — iatrogenic.
• Recurrent oral aphthae, genital ulcers, uveitis — Behçet disease (pulmonary artery aneurysm). ^[1]

Atypical presentation:^[4]

• Elderly — blunted cough reflex (blood pools, aspiration risk higher), comorbidity, frequently on anticoagulants; a small bleed can be life-threatening.
• Immunocompromised — opportunistic infection (invasive aspergillosis, TB, CMV) and thrombocytopenia; may present with little blood but extensive infiltrates.
• Anticoagulated — an occult lesion (carcinoma, AVM) unmasked; never assume the anticoagulant is the sole cause.
• Cystic fibrosis — recurrent episodes; baseline lung function is poor, so even moderate bleeds are dangerous. ^[1]

Massive haemoptysis: rapid onset, brassy cough, large volume of bright-red blood and clots, dyspnoea, tachypnoea, and signs of airway compromise (stridor, falling SpO2, inability to clear secretions, agitation then obtundation). Shock is late and indicates the bleed is enormous.^[1]

Differential Diagnosis

Always work through the causes by category (above) and decide the most likely from the clinical picture. The can't-miss diagnoses that must be actively excluded in every patient are bronchial carcinoma, TB, PE and diffuse alveolar haemorrhage.^[3][4]

The mimics to exclude at the bedside are the non-pulmonary sources: epistaxis (swallowed then coughed), gingival bleeding, haematemesis (aspirated), and factitious causes (food dye, Munchausen). A careful upper-airway inspection and a precise history of the act (cough vs vomit) resolve most. ^[1]

The rare-but-classic causes that win viva marks: mitral stenosis (mid-diastolic murmur), Behçet disease and Hughes–Stovin syndrome (pulmonary artery aneurysm), Goodpasture/anti-GBM (pulmonary–renal syndrome), and the Rasmussen aneurysm (PA pseudoaneurysm in a chronic TB cavity). ^[1]

The four causes examiners contrast head-to-head — memorise the discriminator for each:^[3][4]

• Carcinoma vs TB vs bronchiectasis vs PE — a smoker over 40 with weight loss and a mass is carcinoma; a young patient with fever, night sweats and an apical cavity is TB; years of daily purulent sputum with tram-track on HRCT is bronchiectasis; sudden dyspnoea and pleuritic pain with a clear CXR (or wedge) and risk factors is PE.
• Pulmonary–renal syndromes — if haemoptysis coexists with acute kidney injury, haematuria and bilateral infiltrates, think ANCA vasculitis (GPA, MPA) or anti-GBM disease (Goodpasture); the discriminator is the ANCA pattern (PR3/c-ANCA in GPA, MPO/p-ANCA in MPA) and anti-GBM antibodies, confirmed by renal biopsy.
• Drug-induced — anticoagulants, cocaine (parenchymal damage), propylthiouracil and penicillamine (DAH), and trimellitic anhydride (occupational). ^[1]

Clinical & Bedside Assessment

ABCDE first. In massive haemoptysis the airway takes priority — assess airway patency, ability to cough and clear blood, SpO2, RR, BP, conscious level.^[1][4]

Upper-airway inspection (ENT): inspect the nose, oropharynx, gums and (if possible) larynx to exclude epistaxis or pharyngeal bleeding before concluding the source is pulmonary. This is the first step and is frequently forgotten.^[3]

Respiratory examination to localise the bleeding lung: ^[1]

• Reduced air entry / breath sounds on the bleeding side (bronchial obstruction by blood or clot).
• Crackles, rhonchi over the bleeding lobe.
• Signs of consolidation (pneumonia, infarction), dullness (effusion/haemothorax), cavity (TB, abscess, mycetoma).
• A silent, dull hemithorax suggests collapse or effusion. ^[1]

General examination — high-yield pointers: ^[1]

• Finger clubbing — carcinoma, bronchiectasis, idiopathic pulmonary fibrosis, lung abscess.
• Cachexia, supraclavicular (Virchow) lymphadenopathy — malignancy.
• Telangiectasia of lips/tongue/fingers — Osler–Weber–Rendu (pulmonary AVM).
• Mitral facies, loud S1, mid-diastolic rumble, AF — mitral stenosis.
• Purpura, petechiae, mucosal bleeding — coagulopathy/thrombocytopenia.
• Nasal septum perforation, saddle nose, oral ulcers — granulomatosis with polyangiitis (GPA).
• Peripheral oedema, haematuria on dipstick — DAH with renal involvement (pulmonary–renal syndrome).
• Leg swelling/tenderness — DVT/PE. ^[1]

Triage decision — the skill that matters: the bedside assessment culminates in a single decision — is this patient safe for an outpatient work-up, or do they need the massive-haemoptysis pathway? The answer hinges on volume per unit time, airway patency, oxygenation, haemodynamics, and respiratory reserve (FEV1, baseline exercise tolerance, age). A smoker over 40 with even a small volume of blood, weight loss, or a mass on CXR is not an outpatient — they need urgent CT and bronchoscopy to exclude carcinoma. Conversely, a young non-smoker with a single episode of blood-streaked sputum, a normal CXR, and no red flags can be safely investigated as an outpatient.^[3]

Investigations

First-line (in parallel with resuscitation): the evaluation combines laboratory tests (full blood count, coagulation screen, electrolytes, creatinine, blood grouping and crossmatch), imaging with chest X-ray and CT, and bronchoscopy, alongside urinalysis whenever a pulmonary–renal syndrome is plausible.^[3]

Imaging: ^[1]

• Chest X-ray — first-line; localises the bleed in roughly 60 to 80 percent but is normal in 20 to 30 percent (PE, early carcinoma, central lesion, DAH early). Patterns: apical cavity (TB, mycetoma), mass (carcinoma), consolidation (pneumonia, infarct), bilateral infiltrates (DAH, pulmonary oedema), tram-track (bronchiectasis), wedge (PE infarct), meniscus (effusion).^[3]
• CT thorax (often CT pulmonary angiography, CTPA) — the gold-standard / most sensitive test for localising the source and cause; defines bronchial artery anatomy for embolisation, masses, cavities, AVMs, DAH, PE. Perform once the patient is stable; in massive haemoptysis do not delay airway control for CT.^[4]
• Bronchoscopy — flexible (submassive, awake patient — diagnosis + topical therapy) vs rigid (massive, allows ventilation + large-bore suction + tamponade). Diagnostic AND therapeutic. Timing is debated — early bronchoscopy (within 24 h) improves localisation; in massive bleeding the bleeding side is hard to see, so CTA often guides.^[4]

Sputum (when TB/infection suspected): AFB microscopy and mycobacterial culture (TB), GeneXpert/CBNAAT (rapid TB PCR + rifampicin resistance), Gram stain and culture (pneumonia/abscess), cytology (malignancy). Send three early-morning samples for AFB.^[3]

Autoimmune panel if DAH suspected: ANCA (PR3/c-ANCA points to GPA; MPO/p-ANCA points to MPA/EGPA), anti-GBM (Goodpasture), ANA, dsDNA, complement, and renal biopsy.^[4]

Chest X-ray and CT patterns that name the cause — a high-yield viva area:^[3][4]

• Apical cavity with an air-crescent / intracavitary mass — aspergilloma (fungus ball in an old TB cavity); the "monod sign".
• Apical cavity without fungus ball, fibrosis, volume loss — post-TB bronchiectasis or active cavitary TB.
• Spiculated / coin lesion, hilar or mediastinal nodes — bronchogenic carcinoma.
• Bilateral, perihilar airspace opacification that spares the apices — diffuse alveolar haemorrhage (or pulmonary oedema).
• Peripheral wedge-shaped density — pulmonary infarct (PE).
• Tram-track, signet-ring, varicose bronchi — bronchiectasis on HRCT.
• Tortuous, dilated enhancing vessels — pulmonary AVM (Osler–Weber–Rendu); confirmed by CT angiography.
• Enhancing nodule in a cavity wall — Rasmussen aneurysm (pulmonary artery pseudoaneurysm).
• Normal CXR — think PE, early/small carcinoma, bronchial carcinoid, DAH early, tracheal/bronchial lesion not yet visible. ^[1]

Bronchoscopy timing — the controversy: early bronchoscopy (within 24 h of a non-massive bleed) improves the localisation yield because active bleeding points the endoscopist to the source. In massive haemoptysis, however, the airway is flooded and the bleeding side is impossible to see — here CT angiography (CTA) is more useful to map the culprit bronchial artery before embolisation. The modern sequence for massive bleeds is therefore secure the airway, then CTA, then BAE, with rigid bronchoscopy reserved for airway control and tamponade. Flexible bronchoscopy is best suited to submassive bleeds in the stable, awake patient.^[4] Named thresholds — reproduced verbatim (a favourite exam area):

• "Massive" haemoptysis — classical volume thresholds: definitions vary widely — over 100 mL/24h at the lower end, 300 to 600 mL/24h in many texts, up to over 1000 mL/24h. The modern functional definition: any volume threatening the airway, gas exchange or haemodynamics.^[1][2][4][8]
• Bronchial artery embolisation (BAE): immediate haemostasis in 75 to 98 percent (technical success about 97 percent); recurrence in about a quarter over months; spinal-cord ischaemia (artery of Adamkiewicz) is the feared complication.^[3][12][13]

Management — Massive Haemoptysis Algorithm

Enlarge

In massive (life-threatening) haemoptysis, resuscitation and airway control come first, with simultaneous activation of the bronchoscopy, interventional radiology (IR), and surgical teams.^[1][4]

Step 1 — Airway and breathing

1. High-flow oxygen — target SpO2 94 to 98 percent, or 88 to 92 percent in COPD/CO2-retainers.^[1]
2. Position the BLEEDING LUNG DOWN (dependent, lateral decubitus) to protect the good lung from aspiration of blood. Sit up if mild and stable. Placing the good lung down drowns the patient — a classic and lethal error.
3. Vigorous large-bore suction to keep the airway clear of blood and clot.

Step 2 — Circulation and coagulation

4. Two large-bore IV cannulae, send bloods and crossmatch early, give balanced crystalloid and blood transfusion for shock; monitor SpO2, HR, BP, urine output, GCS.
5. Reverse anticoagulation — stop anticoagulants/antiplatelets and correct coagulopathy with the reversal strategy appropriate to the agent identified; always look for the underlying lesion.^[4]

Step 3 — Secure the airway if threatened

6. Endotracheal intubation with a large single-lumen tube (at least 8 mm internal diameter) to allow passage of a bronchoscope and large-bore suction catheter, OR a double-lumen tube / bronchial blocker for selective lung ventilation (isolate the bleeding lung). Transfer to ITU. Never intubate with a small tube — you cannot pass a scope or suction clots through it. ^[1]

Escalation trigger: any patient with airway compromise, falling SpO2, inability to clear blood, or shock must be intubated and moved to ITU immediately.^[4]

Management — Definitive & Stepwise

Once the airway is secure, the goal is to localise and control the source.^[1][2][4]

Bronchoscopic control (rigid preferred for massive — ventilation + tamponade + working channel):^[4]

• Iced saline lavage of the bleeding bronchus (vasoconstriction).
• Topical adrenaline 1:20,000 (or 1:10,000) instilled via the scope.
• Balloon tamponade — a Fogarty catheter or bronchial blocker inflated in the bleeding segment to occlude it; leave up to 24 to 48 h.
• Topical thrombin / fibrinogen-thrombin glue.
• Argon plasma coagulation (APC), Nd:YAG laser, cryotherapy — to coagulate or debulk a visible bleeding lesion (carcinoid, carcinoma). ^[1]

Rigid vs flexible bronchoscopy — when each: the rigid scope is the instrument of choice for massive haemoptysis because it provides a large working channel (large-bore suction, tamponade balloons, rigid forceps for clot extraction), controlled ventilation, and the mechanical ability to tamponade a bleeding segment by packing with gauze or balloon. Its limitation is that it reaches only the central airways. The flexible scope is ideal for submassive bleeds in the awake, stable patient: it reaches segmental and subsegmental bronchi, allows diagnosis and topical therapy, and can be passed through a rigid scope or large single-lumen tube when both central and peripheral access are needed.^[4]

Practical sequence at the scope: once the bleeding side is identified, isolate the lung (bronchial blocker or double-lumen tube), suction clot from the airway, then apply interventional bronchoscopic local treatment to the accessible bleeding site — iced-saline lavage, topical adrenaline, balloon tamponade, or thermal coagulation (APC/laser) for a visible lesion. The rigid scope — large working channel, controlled ventilation — is preferred while bleeding is active.^[3][4]

Bronchial artery embolisation (BAE) — first-line intervention

BAE is the first-line intervention for massive haemoptysis when bronchoscopy cannot control the bleed, and has displaced surgery as the default definitive therapy.^[2][6]

Technique: ^[1]

1. Pre-procedure CT angiogram (CTA) maps the bronchial arteries and any abnormal systemic collaterals (intercostal, subclavian, internal mammary, inferior phrenic) that may be feeding the bleed.
2. Under fluoroscopy, the interventional radiologist catheterises the culprit bronchial artery from a femoral arterial access, usually with a coaxial microcatheter system.
3. Embolisation with polyvinyl alcohol (PVA) particles, gelatin sponge (Gelfoam), or microspheres (tris-acryl gelatin) until flow is abolished.
4. All feeding arteries are embolised to prevent early rebleed from collaterals. ^[1]

Caveats: the artery of Adamkiewicz (a spinal feeder arising from a bronchial or intercostal artery) must be identified on CTA before embolisation — inadvertent embolisation causes anterior spinal artery syndrome and paraplegia.^[13] Non-target embolisation to the coronary, cerebral or mesenteric circulation causes ischaemia and stroke. Contrast-induced nephropathy and recurrence (pooled about 25 percent; highest in aspergilloma and active TB) are the main drawbacks.^[2][6][12]

Surgery — last resort

Surgery is last resort, reserved for uncontrolled bleeding that is localised and surgically resectable (single lobe, good lung function, fit patient). Emergency lobectomy (or pneumonectomy) carries operative mortality of 37 to 43 percent in published series. Selective-lung ventilation and stabilisation before resection improve outcome.^[5][8]

Pharmacological and supportive: tranexamic acid as an adjunct — a randomised trial of inhaled TXA in non-massive haemoptysis achieved resolution within five days in 96 versus 50 percent on placebo and reduced invasive procedures, while a Cochrane review found overall evidence insufficient but compatible with shorter bleeding duration; treat the underlying cause (TB therapy, malignancy treatment, vasculitis immunosuppression, antifungals). ^[9][17]

Non-massive haemoptysis management: investigate the cause (CXR + CT + bronchoscopy), treat the underlying disease, and discharge only if stable with small volume, no red flags, and a normal or explained CXR. Arrange follow-up CXR at 6 to 8 weeks in smokers over 50 to exclude an occult malignancy that was too small to see initially.^[3]

Specific Subtypes & Scenarios

• Diffuse alveolar haemorrhage (DAH) — bilateral infiltrates, anaemia, dyspnoea; haemoptysis may be absent (up to half of cases). Capillaritis (ANCA, anti-GBM, immune-complex) vs bland (coagulopathy, mitral stenosis, drugs). Treat the underlying cause: high-dose glucocorticoids plus cyclophosphamide or rituximab for ANCA-associated capillaritis; plasma exchange combined with cyclophosphamide and glucocorticoids for anti-GBM disease. Bronchoalveolar lavage shows progressively bloodier returns.^{[4][11][18][19]}
• Aspergilloma (mycetoma) — a fungus ball in a pre-existing cavity (post-TB, sarcoid); massive, recurrent haemoptysis. Surgery is the mainstay in fit patients; BAE temporises until definitive eradication; systemic azoles effective in 50 to 80 percent; intracavitary or endobronchial antifungal therapy for the unfit.^[16]
• Iatrogenic pulmonary artery rupture (from a PA/Swan–Ganz catheter) — sudden haemoptysis in the catheterised, often anticoagulated patient. Advance the catheter and inflate the balloon to tamponade, isolate the bleeding lung (bronchial blocker / double-lumen tube), reverse coagulopathy, urgent thoracic surgery/IR; mortality is high.
• Cystic fibrosis with recurrent/massive haemoptysis — BAE when initial medical management fails, repeat for recurrence; surgery is a last resort; bilateral disease makes surgery hazardous — refer for transplant assessment in advanced disease.^[20]
• Bronchial carcinoid — a highly vascular tumour (often central, in younger non-smokers); recurrent bleeds; surgical resection (sleeve lobectomy) is both diagnostic and curative; bronchoscopic debulking/APC for palliation.
• Rasmussen aneurysm — pulmonary artery pseudoaneurysm adjacent to a chronic TB cavity; massive haemoptysis; diagnosed on CT pulmonary angiography and treated by selective pulmonary artery embolisation (or surgery), alongside anti-TB therapy.^[15]
• Pulmonary AVM (Osler–Weber–Rendu / HHT) — dyspnoea, cyanosis, clubbing, paradoxical emboli/stroke; recurrent minor or massive haemoptysis; treated by coil or vascular plug embolisation; screen the family.
• Pregnancy with haemoptysis — PE is the leading cause (pregnancy is a 5-fold prothrombotic state); TB in endemic regions. Use chest X-ray with shielding and CTPA judiciously (the radiation risk to the fetus is low and outweighed by the risk of a missed PE); BAE is feasible; avoid warfarin (teratogenic; use LMWH).^[3]

Complications & Pitfalls

Complications:^[1][5]

• Asphyxia and death from aspiration of blood — the principal mode of death.
• Hypovolaemic / haemorrhagic shock (less common; indicates an enormous bleed).
• Aspiration pneumonia, atelectasis (clot obstruction), airway obstruction by clot, ARDS.
• After BAE: recurrence (about a quarter), contrast-induced nephropathy, anterior spinal artery syndrome / paraplegia (Adamkiewicz), stroke and ischaemia from non-target embolisation (e.g. broncho-oesophageal artery).
• After emergency surgery: bronchopleural fistula, empyema, respiratory failure, high mortality. ^[1]

Classic pitfalls: ^[1]

• Mistaking haematemesis for haemoptysis (or vice versa) — leading to wrong investigations and the wrong team.
• Failing to localise the bleeding lung before positioning — placing the good lung down drowns the patient.
• Over-sedating the patient for bronchoscopy — depressing the cough and airway reflexes and accelerating aspiration.
• Intubating with a small tube — cannot pass a bronchoscope or suction large clots; use at least 8 mm.
• Delaying BAE while awaiting CT in an unstable patient — airway and embolisation first.
• Assuming the anticoagulant is the sole cause — always look for an underlying lesion.
• Missing diffuse alveolar haemorrhage — bilateral infiltrates with anaemia and renal failure; haemoptysis may be absent.
• Forgetting PE in the patient with haemoptysis, dyspnoea and a clear CXR. ^[1]

Prognosis & Disposition

• Mild haemoptysis — self-limited in about 90 percent; outpatient work-up (CXR, consider CT, sputum, bronchoscopy if indicated) with follow-up imaging in smokers and older patients to exclude occult malignancy.^[3]
• Massive haemoptysis mortality — 50 to 85 percent when treated conservatively; BAE with critical care is now standard and reduces haemoptysis-related mortality versus conservative treatment alone.^[3][6][8]
• Poor-prognosis predictors: malignancy and lower presenting haemoglobin independently predict in-hospital mortality; massive bleeds and aspiration into the good lung carry the worst outlook.^[21]
• Disposition: massive → ITU/HDU with airway secured and IR/surgery on standby; moderate → respiratory ward with close monitoring and crossmatched blood; mild → outpatient if stable with no red flags and a normal CXR.^[4]

Prevention of recurrence is cause-specific:^[2][4]

• Treat the underlying disease to completion — full anti-TB therapy, eradication therapy for bronchiectasis, oncological treatment for carcinoma, immunosuppression for vasculitis.
• Control modifiable factors — smoking cessation (the single most effective lung-cancer and chronic-bronchitis prevention measure), optimise airway clearance in bronchiectasis/CF (physiotherapy, mucolytics, prophylactic antibiotics), and anticoagulation review in patients with a known pulmonary lesion.
• In aspergilloma, because rebleed is the rule, surgical resection in fit patients is preventive; repeat BAE is offered to those unfit for surgery.
• In pulmonary AVM (HHT), embolisation of all feeding arteries plus family screening (autosomal dominant) prevents both rebleed and paradoxical embolism.
• After BAE, surveillance for recurrence (rebleed in about a quarter) — educate the patient to return promptly with any fresh bleed. ^[1]

Special Populations

• Children — haemoptysis is uncommon. Causes: foreign-body aspiration (a leading cause in toddlers), infection (pneumonia, TB), bronchiectasis (CF), vascular malformation, tracheo-oesophageal fistula. A small airway means a small volume can obstruct; rigid bronchoscopy under GA is both diagnostic and therapeutic.
• Pregnancy — PE is the leading cause (5-fold prothrombotic state); TB in endemic regions. Shielded CXR and CTPA are acceptable; BAE is feasible; avoid warfarin (use LMWH).^[3]
• Elderly — blunted cough, comorbidity, anticoagulants and high malignancy risk; lower threshold for hospital admission, imaging and bronchoscopy.
• Immunocompromised — invasive aspergillosis (angioinvasive), TB, CMV, thrombocytopenia; broad differential, lower threshold for bronchoscopy/BAL.
• Anticoagulated / coagulopathic — reverse the agent; exclude an underlying lesion (do not attribute the bleed to the anticoagulant alone).
• Cystic fibrosis — recurrent episodes; BAE first-line; consider transplant referral for advanced disease.

Evidence, Guidelines & Regional Differences

Landmark evidence and reviews:^{[1][2][4][5][6]}

• Jean-Baptiste (Crit Care Med 2000) — established the modern approach to massive haemoptysis (airway, bronchoscopy, BAE).
• Davidson & Shojaee (Chest 2020) and Deshwal & Mehta (Semin Respir Crit Care Med 2021) — comprehensive stepwise algorithms confirming airway-first and BAE first-line.^[1][4]
• Fan et al (BMC Pulm Med 2024) — systematic review and meta-analysis supporting BAE over conservative management.^[6]
• Tranexamic acid — randomised evidence (inhaled TXA) and a Cochrane review show modest benefit in non-massive haemoptysis; evidence in massive haemoptysis remains weak and the drug is an adjunct, never a definitive therapy.^[9][17]

Modern consensus shift — away from rigid volume thresholds toward the functional definition of life-threatening haemoptysis, recognising that a small bleed can kill a patient with poor reserve.^[1][2]

^{[1] [1] [1]}

Exam Pearls

• Commonest cause worldwide = TB (up to 40 percent of cases in low/middle-income settings); in high-income regions malignancy and bronchiectasis predominate.^[3][14]
• Over 90 percent of massive haemoptysis arises from the BRONCHIAL (high-pressure systemic) arteries — that is why the bleed is brisk and why BAE works.^[1][7]
• Death is from ASPHYXIA, not exsanguination — protect the airway first; even a small amount of blood can be fatal.^[1][5]
• Position the BLEEDING LUNG DOWN to protect the good lung.^[1]
• BAE is first-line for massive haemoptysis; surgery is last resort (emergency operative mortality 37 to 43 percent).^[8]
• Rigid (not flexible) bronchoscopy for massive haemoptysis — ventilation + tamponade.
• Beware the artery of Adamkiewicz during BAE — anterior spinal artery syndrome / paraplegia.^[2][13]
• Haemoptysis vs haematemesis: bright red, frothy, alkaline, coughed vs dark coffee-ground, acidic, vomited.
• Aspergilloma (fungus ball) + massive haemoptysis → surgical resection is the mainstay (BAE temporises).^[16]
• Diffuse alveolar haemorrhage may have NO haemoptysis — anaemia + bilateral infiltrates + renal failure → think ANCA / anti-GBM (Goodpasture); treat with glucocorticoids plus cyclophosphamide or rituximab, and plasma exchange for anti-GBM.^[11][18][19]
• Rasmussen aneurysm = pulmonary artery pseudoaneurysm in a chronic TB cavity causing massive haemoptysis.
• Clear CXR + dyspnoea + pleuritic pain = PE — do not be reassured by a normal film.^[3]
• Mitral stenosis — rare but classic; look for the mid-diastolic murmur.
• Massive = any volume threatening airway/gas exchange (functional definition) — the modern threshold, not a rigid mL cut-off.^[1][2]

Ward-round test — three stems, thirty seconds each

Stem 1 — the smoker from the opening vignette (answer)ShowHide

A 58-year-old smoker with a spiculated right upper lobe mass, clubbing and weight loss coughs up half a cup of bright red blood. CXR confirms the mass. What is the next step? Model: This is bronchogenic carcinoma until proven otherwise — smoker over 40, weight loss, clubbing, a new mass. The bleed is sub-massive (no airway threat, haemodynamically stable), so the pathway is admit, oxygen, crossmatch, reverse any anticoagulation, then urgent contrast CT chest and flexible bronchoscopy with biopsy for tissue diagnosis and molecular profiling. Do not discharge a smoker over 40 with unexplained haemoptysis and a mass; arrange follow-up imaging at 6 to 8 weeks even if the initial CXR were normal.^[1][3]

Stem 2 — the bleed that drops the saturation (answer)ShowHide

An intubated patient on the ward with known bronchiectasis coughs (round the tube) 300 mL of blood in 20 minutes and the SpO2 falls to 84 percent. What do you do in the next five minutes? Model: This is massive, life-threatening haemoptysis — death is from asphyxia, not exsanguination. Place the bleeding lung DOWN (lateral decubitus, affected side dependent) to protect the good lung, suction the airway, high-flow oxygen, two large-bore IVs and crossmatch, reverse anticoagulation, then rigid bronchoscopy for tamponade (iced saline, topical adrenaline, balloon) and activation of interventional radiology for bronchial artery embolisation as the first-line definitive intervention. Surgery (lobectomy) is the last resort, reserved for localised, resectable, uncontrolled bleeding. The classic lethal error is putting the good lung down and drowning the patient.^[1][3][4][7]

Stem 3 — clear CXR, dyspnoea and a rising creatinine (answer)ShowHide

A 35-year-old non-smoker presents with mild haemoptysis, dyspnoea, bilateral infiltrates on CXR, a haemoglobin of 78 g/L and a creatinine of 320 micromol/L with haematuria on dipstick. What is the diagnosis, and what is the first test? Model: This is a pulmonary-renal syndrome — diffuse alveolar haemorrhage with rapidly progressive glomerulonephritis. The two named culprits are ANCA-associated vasculitis (GPA, MPA) and anti-GBM disease (Goodpasture). Send ANCA (PR3/MPO) and anti-GBM antibodies urgently, confirm with renal biopsy, and treat with high-dose glucocorticoids, cyclophosphamide and plasma exchange (plasma exchange combined with cyclophosphamide and glucocorticoids is standard for anti-GBM). Note that haemoptysis may be absent in DAH because the blood stays in the alveolar space — anaemia with bilateral infiltrates and renal failure is the real clue.^{[4][10][11][19]}

References21ShowHide

1. [1]Davidson K, Shojaee S. Managing Massive Hemoptysis Chest, 2020.PMID 31374211
2. [2]Prey B, Francis A, Williams J, Krishnadasan B. Evaluation and Treatment of Massive Hemoptysis Surg Clin North Am, 2022.PMID 35671767
3. [3]Ittrich H, Bockhorn M, Klose H, Simon M. The Diagnosis and Treatment of Hemoptysis Dtsch Arztebl Int, 2017.PMID 28625277
4. [4]Deshwal H, Sinha A, Mehta AC. Life-Threatening Hemoptysis Semin Respir Crit Care Med, 2021.PMID 32862418
5. [5]Yendamuri S. Massive Airway Hemorrhage Thorac Surg Clin, 2015.PMID 26210922
6. [6]Fan S, Cheng X, Wang X, Liu Y, He W, Chen H. Bronchial artery embolization versus conservative treatment for hemoptysis: a systematic review and meta-analysis BMC Pulm Med, 2024.PMID 39215233
7. [7]Yoon W, Kim JK, Kim YH, Chung TW, Kang HK. Bronchial and nonbronchial systemic artery embolization for life-threatening hemoptysis: a comprehensive review Radiographics, 2002.PMID 12432111
8. [8]Cody O'Dell M, Gill AE, Hawkins CM. Bronchial Artery Embolization for the Treatment of Acute Hemoptysis Tech Vasc Interv Radiol, 2017.PMID 29224659
9. [9]Prutsky G, Domecq JP, Salazar CA, Accinelli R. Antifibrinolytic therapy to reduce haemoptysis from any cause Cochrane Database Syst Rev, 2016.PMID 27806184
10. [10]Boyle N, O'Callaghan M, Ataya A, Gupta N, Keane MP, Murphy DJ, McCarthy C. Pulmonary renal syndrome: a clinical review Breathe (Sheff), 2022.PMID 36865943
11. [11]Murray J, O'Brien S, Mitchell PD. Diffuse Alveolar Hemorrhage Semin Respir Crit Care Med, 2026.PMID 41130281
12. [12]Tao Y, Li J, Su R, Zhou M, Zhu H, Sun Z. The efficacy, safety, and related factors of bronchial artery embolization for hemoptysis: a systematic review and meta-analysis with subgroup analysis Cardiovasc Diagn Ther, 2024.PMID 39513143
13. [13]Padgett M, Abi-Jaoudeh N, Benn BS, Rahimian R, Nelson K. Anterior Cord Syndrome after Embolization for Malignant Hemoptysis Semin Intervent Radiol, 2019.PMID 31123382
14. [14]Mishra PR, Choudhury K, Gopinath B. Advances and challenges in the management of haemoptysis in the emergency department: A narrative review Lung India, 2026.PMID 42377159
15. [15]Ng SY, Leong KS. Rasmussen Aneurysm in Pulmonary Tuberculosis-A Malaysian Case Study With Review of Global Literature Respirol Case Rep, 2026.PMID 41777482
16. [16]Lang M, Lang AL, Chauhan N, Gill A. Non-surgical treatment options for pulmonary aspergilloma Respir Med, 2020.PMID 32217289
17. [17]Wand O, Guber E, Guber A, Epstein Shochet G, Israeli-Shani L, Shitrit D. Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial Chest, 2018.PMID 30321510
18. [18]Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update Ann Rheum Dis, 2024.PMID 36927642
19. [19]McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease-treatment standard Nephrol Dial Transplant, 2025.PMID 40973182
20. [20]Hurt K, Simmonds NJ. Cystic fibrosis: management of haemoptysis Paediatr Respir Rev, 2012.PMID 23069116
21. [21]Pepele MS, Derya S, Murat M. Triage risk stratification in emergency department hemoptysis: associations of hemoglobin and malignancy with in-hospital mortality Am J Emerg Med, 2025.PMID 41138308